Table 5 Disease outcome following IMRT in selected published series including the own study
From: IMRT using simultaneously integrated boost (SIB) in head and neck cancer patients
Authors | HNC cohorts | N patients | LC (%) | NC (%) | LRC | DC (%) | OAS (%) | time point |
|---|---|---|---|---|---|---|---|---|
Eisbruch et al [11] | oro/hypo/OC | 133 | 94/77/60 | 3y | ||||
Dawson et al [1] | HNC w/o NPC | 58 | 79 | 2y | ||||
Own study | HNC w/o NPC | 115 | 77 | 87 | 78 | 86 | 2y | |
Eisbruch et al [11] | dIMRT/pIMRT | 60/73 | 81/84 | 3y | ||||
Chao et al [4] | dIMRT/pIMRT | 31/43 | 78/95 | 84/94 | 87 | 3y | ||
Chao et al [5] | dIMRT/pIMRT | 52/74 | 79/90 | 2y | ||||
own study | dIMRT/pIMRT | 80/34 | 81/91 | 86/97 | 92/88 | 75/79 | 2y | |
Eisbruch et al [11] | oro | 80 | 94 | 3y | ||||
Garden et al [in 6] | oro | 80 (T1-2N0) | 94 | 2y | ||||
De Arruda 17 | oro | 50 | 98 | 88 | 84 | 98 | 2y | |
Huang et al [in 6] | oro | 41 | 94 | 89 | 91 | 89 | 2y | |
Own study | oro | 56 | 88 | 93 | 93 | 87 | 2y |